Riskpilot← Back to searchSign inGet full accessCommit Biologics ApS
APSActiveCVR 42642649Universitetsbyen 81Research and experimental development on natural sciences and engineering · NACE 7210Est. 202120 employees
Revenue 2025
DKK -23,4M
-26% vs 2024
EBITDA margin
167.8%
+13% vs 2024
Equity ratio
97.7%
Financial strength
Net profit 2025
DKK -33,8M
+14% vs 2024
| Revenue | DKK -23,4M | -26% |
| EBITDA | DKK -39,2M | +13% |
| Net profit | DKK -33,8M | +14% |
| Total assets | DKK 38,8M | +59% |
| Equity | DKK 37,9M | +63% |
| Employees | 20 | — |
Legal name
Commit Biologics ApS
CVR number
42642649
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. september 2021
Share capital
DKK 208.371
Employees
20 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er fremstilling af farmaceutiske præparater, forskning og eksperimentel udvikling indenfor bioteknologi.
Address
Universitetsbyen 81
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | -2.722 | -13.580 | -31.408 | -23.365 |
| Staff expenses | -1.725 | -7.084 | -13.864 | -15.849 |
| EBITDA | -4.448 | -20.664 | -45.272 | -39.214 |
| Depreciation & amort. | -0 | -111 | -205 | -256 |
| EBIT | -4.448 | -20.775 | -45.477 | -39.469 |
| Net financials | -185 | 244 | 616 | 188 |
| Profit before tax | -4.633 | -20.531 | -44.861 | -39.281 |
| Tax | -317 | -3.235 | -5.500 | -5.500 |
| Net profit | -4.316 | -17.296 | -39.361 | -33.781 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 41.013 | 23.326 | 24.451 | 38.808 |
| Equity | 39.875 | 22.579 | 23.218 | 37.898 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 1.138 | 747 | 1.233 | 910 |
| Total debt | 1.138 | 747 | 1.233 | 910 |
EBITDA margin
-3921380300.0%
This company
15.8%
Market median
-24818862758% vs market
20222025
Equity ratio
97.7%
This company
38.2%
Market median
+156% vs market
20222025
Return on equity
-89.1%
This company
18.4%
Market median
-584% vs market
20222025
Net profit margin
-3378107900.0%
This company
8.1%
Market median
-41705035902% vs market
20222025
Asset turnover
-0.60×
This company
1.12×
Market median
-154% vs market
20222025
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20222025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2021-09-01 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HG Management | Management | 2021 | — | — |
MB Management | Management | 2021 | — | — |
KR Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
DV Management | Management | 2021 | — | — |
MW Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
TL Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Novo Holdings A/S | Company | 25.0% | 25.0% | 2026 |
| Individual | 25.0% | 25.0% | 2026 | |
Commit Biologics Holding ApS | Company | 15.0% | 15.0% | 2026 |
| Individual | 15.0% | 15.0% | 2026 | |
BII Holdings A/S | Company | 5.0% | 5.0% | 2023 |
BioInnovation Institute Fonden | Company | 5.0% | 5.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Commit Biologics ApS Board members of Commit Biologics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Heidi Gytz Olesen | Management | 0 companies |
| Mikael Becher Lykkegaard Winkler | Management | 0 companies |
| Krishna Reddy Polu | Chief Executive Officer | 0 companies |
| Dennis Vestergaard Pedersen | Management | 0 companies |
| Mikkel Wandahl Pedersen | Chief Executive Officer | 0 companies |
| Thomas Lars Andresen | Chief Executive Officer | 0 companies |
| Eva Van Overmeire | Board of Directors | 0 companies |
| Pieter Jeroen Bakker | Board of Directors | 0 companies |
| Janine Schuurman | Board of Directors | 0 companies |
| Anker Gunvald Lundemose | Chairman | 0 companies |
| Nick Stub Laursen | Board of Directors | 0 companies |
| Roderick Verhelst | Board of Directors | 0 companies |